-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target

Benzinga·10/16/2026 18:21:41
Listen to the news
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.